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ABSTRACT
We present the case of a 70-year-old male patient with fever of unknown origin after a long period of convalescence from a previous 
admission to a chronic care hospital. During the admission, multiple combinations of antibiotic and antifungal treatments were prescribed, 
but with persistent fever and, eventually, neutropenia (200 lymphocytes, 0 neutrophils). Given the suspicion of infection at bone marrow 
level, a biopsy was performed as was serology of Leishmania, both diagnostic determinations. Treatment with amphotericin B liposomal 
resulted in a good outcome.
LEARNING POINTS
• Visceral leishmaniasis is a rare aetiology of neutropenia, which causes an important constitutional syndrome and long-standing fever.
•	 However,	this	pathology	is	endemic	in	areas	of	the	Mediterranean	Sea,	which	is	well	known	for	migratory	flows.
• High clinical suspicion of leishmaniasis is necessary in patients with fever of long evolution, hepatomegaly or splenomegaly, fever and 
constitutional syndrome, and from endemic areas.
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INTRODUCTION
Visceral leishmaniasis is a disease caused mainly by Leishmania donovani and Leishmania infantum. The main reservoirs in our environment 
are	dogs,	although	mice	and	other	wild	animals	can	also	transmit	the	flagellated	protozoan	through	the	bite	of	the	female	sandfly.	In	Spain,	
there have been relatively common outbreaks of Leishmania, such as that which occurred in the Community of Madrid between 2009 and 
2012. Its incidence in our environment is 0.45 cases per 100,000 inhabitants. This is because the disease is present endemically in areas of 
the	Mediterranean,	more	specifically	in	rural	areas,	mountain	towns	and	peri-urban	regions.
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CASE DESCRIPTION
A 70-year-old Spanish man with a history of hypertension, ex-smoker, ischaemic cardiopathy and chronic heart failure with left ventricular 
ejection	fraction	(LVEF)	in	the	mid-range,	severe	chronic	obstructive	pulmonary	disease	(COPD),	and	chronic	atrial	fibrillation	was	admitted	
to our hospital from the emergency room due to sepsis of probable respiratory origin with acute renal failure and secondary digital toxicity, 
together with pancytopenia. He received combination antibiotic treatment of meropenem with amikacin and daptomycin, as well as 
fluconazole,	later	simplified	to	piperacillin/tazobactam,	in	spite	of	which	the	patient	continued	to	have	asymptomatic	febrile	peaks.	
Serial blood cultures were negative. Following haematology consultation for pancytopenia, probable myelodysplastic syndrome was 
diagnosed, without performing a core biopsy. After respiratory stabilisation and slight improvement of the functional class, the patient was 
transferred to a convalescent hospital for functional recovery and rehabilitation.
He remained in the convalescence hospital for 3 months, however, with progressive worsening of his general condition and persistent fever, 
for which the antibiotics received in the tertiary hospital were progressively reintroduced. Finally, he was transferred to our hospital due to 
persistent high fevers of 5 consecutive days.
On examination this time, he presented with intense sarcopenia together with poor general condition; cardiopulmonary exploration was 
normal, without evidence of visceromegaly in abdominal exploration. A clinical ultrasound was performed which showed an estimated LVEF 
of	45%,	moderate	mitral	insufficiency,	absence	of	pericardial	or	pleural	effusion,	and	absence	of	abdominal	visceromegaly.
In one blood test carried out, the presence of 200 lymphocytes with 0 neutrophils was evidenced, as well as severe thrombocytopenia. In 
the study, serology was performed for HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV), which were all negative, as well as viral load 
of cytomegalovirus (CMV). Serology for Leishmania was positive, with a median title of 1:2560.
Given	 these	 findings,	 it	 was	 decided	 to	 perform	 a	 sternal	 bone	marrow	 biopsy.	 It	 showed	 the	 presence	 of	 parasites	 in	 bone	marrow,	
taxonomically catalogued as Leishmania infantum (Figs. 1, 2, 3 and 4). The patient started treatment with liposomal amphotericin B with good 
clinical evolution, improvement of pancytopenia, and resolution of fever.
Figure 1. Monocyte-macrophage filled with Leishmania amastigotes 
phagocytosed in the cytoplasm and surrounded by granulocytes and thrombocytes 
Figure 2. Megakaryocytes surrounded by Leishmania 
Figure 3. Two cell monocyte-macrophage system with multiple Leishmania 
amastigotes phagocytosed inside 
Figure 4. Free Leishmania amastigotes in the interstitial tissue of the bone marrow
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DISCUSSION 
Usually, Leishmania infection is asymptomatic, a consequence of the ability of the immune system to control parasitic replication. In Europe, 
only 1 in 30 people infected manifest the disease clinically, compared to 1 in 4 people in India, where the disease is endemic. This highlights 
the differences in virulence among several parasitic strains, genetic predisposition, nutritional status, age, and other factors. Subclinical 
infection can be evidenced in serological tests, and manifestations can appear before immunosuppression of the individual that contains the 
parasite in the phagocytic mononuclear system[1, 2].
The main clinical manifestation of visceral leishmaniasis is the syndrome known as kala-azar. The incubation period ranges from 2 to 6 
months, with symptoms of insidious onset in the form of fever, weight loss, and splenomegaly with or without hepatomegaly. Patients may 
present with abdominal discomfort, especially in the left hypochondrium. The spleen can be palpated and usually is not painful[3]. Anaemia, 
neutropenia, eosinopenia, and thrombocytopenia are common in laboratory tests.
The main methods to establish the diagnosis of infection include direct visualisation of the parasite in an extension of a tissue sample 
obtained by biopsy (bone marrow / spleen), culture in special media, and detection by polymerase chain reaction (PCR) of genetic material 
or serology. However, diagnostic certainty is made by direct observation of the parasite[1, 4, 5]. 
The	treatment	of	first	choice	for	visceral	leishmaniasis	is	liposomal	amphotericin	B	3	mg/kg/day	intravenously	in	immunocompetent	patients	
and 4 mg/kg/day in immunosuppressed patients. Meglumine antimoniate can be used instead, or miltefosine or paromomycin sulfate as a 
second choice.
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